An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Trial Details

NCT ID

NCT07033026

Phase

PHASE2

Sponsor

NGM Biopharmaceuticals, Inc

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

NGM120 Q4W
NGM120 Q8W
Placebo given

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368
Los Angeles, California, United States|34.05223,-118.24368
Santa Rosa, California, United States|38.44047,-122.71443
Margate, Florida, United States|26.24453,-80.20644
Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

Documented active diagnosis of colorectal cancer.
Cachexia defined by Fearon criteria of weight loss.
Signed informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →